

Product Update:

tafluprost 15micrograms/mL and timolol 5mg/mL preservative-free eye drops (Taptiqom[®]) **SMC No. (1085/15)**

Santen GmbH

07 August 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

tafluprost 15 micrograms/mL and timolol 5mg/mL preservative-free eye drops (Taptiqom[®]) are accepted for restricted use within NHS Scotland.

Indication under review: Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops.

SMC restriction: to use in patients who have proven sensitivity to preservatives.

The combination product costs less than preservative-free tafluprost and timolol eye drops administered separately.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 14 July 2015.

Chairman
Scottish Medicines Consortium

Published 07 September 2015